NYSE:CRL - Charles River Laboratories Intl. Stock Price, Forecast & News

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Charles River Laboratories Intl. Inc (NYSE:CRL) announced its quarterly earnings data on Wednesday, November, 6th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.64 by $0.05. The medical research company earned $668 million during the quarter, compared to analysts' expectations of $674.08 million. Charles River Laboratories Intl. had a net margin of 9.14% and a return on equity of 21.52%. The firm's revenue was up 14.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.53 EPS. View Charles River Laboratories Intl.'s Earnings History.

Charles River Laboratories Intl. is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Charles River Laboratories Intl..

Charles River Laboratories Intl. updated its third quarter 2019 earnings guidance on Monday, October, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $665-670 million, compared to the consensus revenue estimate of $677.8 million.

12 analysts have issued 12 month target prices for Charles River Laboratories Intl.'s stock. Their forecasts range from $138.00 to $170.00. On average, they expect Charles River Laboratories Intl.'s stock price to reach $154.78 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for Charles River Laboratories Intl..

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Charles River Laboratories Intl..

Headlines about CRL stock have trended extremely positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Charles River Laboratories Intl. earned a media sentiment score of 4.1 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Charles River Laboratories Intl..

Charles River Laboratories Intl. saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 939,900 shares, a decrease of 26.6% from the October 31st total of 1,280,000 shares. Based on an average trading volume of 320,900 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.0% of the shares of the company are sold short. View Charles River Laboratories Intl.'s Current Options Chain.

Some companies that are related to Charles River Laboratories Intl. include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories Intl. investors own include Celgene (CELG), Boeing (BA), Intel (INTC), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Alibaba Group (BABA), Emerson Electric (EMR), Procter & Gamble (PG), Biogen (BIIB) and Cisco Systems (CSCO).

Charles River Laboratories Intl.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.35%), TimesSquare Capital Management LLC (2.06%), Congress Asset Management Co. MA (1.40%), Voya Investment Management LLC (1.23%), First Trust Advisors LP (1.19%) and Fisher Asset Management LLC (0.90%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..

CRL stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Copper Rock Capital Partners LLC, State Street Corp, Fisher Asset Management LLC, Man Group plc, SG Americas Securities LLC, Congress Asset Management Co. MA and Great West Life Assurance Co. Can. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, David Ross Smith, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..

CRL stock was bought by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, TimesSquare Capital Management LLC, Endurant Capital Management LP, Massachusetts Financial Services Co. MA, Voya Investment Management LLC, Monarch Partners Asset Management LLC, Trinity Street Asset Management LLP and Tygh Capital Management Inc.. View Insider Buying and Selling for Charles River Laboratories Intl..

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRL stock can currently be purchased for approximately $146.23.

Charles River Laboratories Intl. has a market capitalization of $7.14 billion and generates $2.27 billion in revenue each year. The medical research company earns $226.37 million in net income (profit) each year or $6.03 on an earnings per share basis. Charles River Laboratories Intl. employs 14,700 workers across the globe.View Additional Information About Charles River Laboratories Intl..

The official website for Charles River Laboratories Intl. is http://www.criver.com/.

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]